Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:81004 |
Name | high-grade B-cell lymphoma double-hit/triple-hit |
Definition | A large B-cell lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma high-grade B-cell lymphoma double-hit/triple-hit |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04479267 | Phase II | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisolone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Methylprednisolone + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | Recruiting | USA | 0 |
NCT05507541 | Phase II | Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 | TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05600686 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05641428 | Phase II | axicabtagene ciloleucel ARI-0001 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) | Recruiting | NLD | 0 |
NCT05664217 | Phase II | NKTR-255 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05755087 | Phase I | BC2059 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05852717 | Phase II | Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05929716 | Phase II | Hu5F9-G4 + Rituximab | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | Withdrawn | 0 | |
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT06045247 | Phase II | Cyclophosphamide + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT06088654 | Phase Ib/II | IPH6501 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | FRA | AUS | 0 |
NCT06090539 | Phase I | BMS-986458 + Rituximab BMS-986458 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Recruiting | AUS | 0 |
NCT06287398 | Phase II | Epcoritamab-bysp Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | Recruiting | AUS | 0 |